Exhibiting at booth 83/84
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Mr Jonathan LewisBusiness Development Director
Dr Steve McConchieCEO
Arcinova is a Contract Research and Development Organisation (CRDO), providing the pharmaceutical industry with a comprehensive range of services.
At Arcinova, we are focused on Process, Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in Development and launched to the Market.
Dr Nathalie HutherEuropean Business Development Manager
Dr Mark ChadwickHead of Business Development
Cresset Discovery Services
Cresset Discovery Services manages and delivers outsourced computational chemistry programs. Our consultants work alongside your chemists to solve problems, provide fresh ideas, remove roadblocks and add direction and insight. We help you reach your next milestone faster and more cost effectively.
Computational chemistry helps your chemists understand as much as possible about the systems they are working on. This makes it easier to direct your resources in the direction most likely to succeed, saving you time and money.
Every client brings a different approach, new science and a fresh way of working. We propose methods that provide answers in the most intelligent and innovative way we can. Collaboration often sparks new and better methods and ideas, through new challenges and by the synergistic nature of contract research.
We have extensive industry experience and a proven track record working on over 200 projects over the last decade with many leading pharmaceutical, biotech, agrochemical, flavor and fragrance companies.
Our discovery services are flexible. By accessing expertise where and when you need it you eliminate unnecessary overheads while obtaining a world class service. Use us as your long term CRO or to help navigate bottlenecks in your project.
Dr Ritesh ChauhanAccount Manager
Crystec applies the latest supercritical fluid (SCF) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec’s modified supercritical anti-solvent (mSAS) technology can be applied to small and large drug molecules in a range of dosage forms.
Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence and fungal infections.
The first product based on SCF technology is expected to launch this year. It is an inhaled product for migraine, exploiting the benefits SCF processing brings to enable exceptional particle size control and deep lung deposition. The particle design and scale-up to GMP for this product were managed by members of the Crystec team.
If you are interested in understanding how mSAS could accelerate your product development, contact us for more information – email@example.com
Ms Catherine HunterBusiness Development Director
Datatrial was founded as a technology company in 1999 with a focus on developing software that would improve the clinical research process. Our goal today remains to allow you to realise the benefits of speedy, real-time access to information helping you to identify, gather and respond to any actions and issues as quickly as possible.
With an in-house team of developers continually improving our products we will ensure we have a simple solution to offer you for all your clinical research needs.
Nucleus is a collaboration tool that brings people, applications and documents together in a single compliant environment. Unlike other vendors in our space, the platform is software agnostic allowing inclusion of other third party solutions. Access can be achieved via single sign on or addition of the relevant link within the Nucleus platform. This enables us to include any number of technologies that may be of value to our customers whilst being aware of industry and legal requirements around data and privacy. With the move towards patient centred research, Nucleus can also provide a place where patients can see their data and also communicate with the key people working in their trial.
Collect, manage and report on your clinical data from a single, scalable system. Whether at the very start or nearing the end of your trial, nowEDC will increase your visibility of the data your sites are working hard to collect, providing you with clean, consistently reliable data.
Ms Amy WrightStrategic Services Manager
Ms Emma BanksCEO
High Force Research
Established in 1988, High Force Research is proud to remain a truly independent UK chemistry CRO. HFR collaborates with discovery groups in synthesising new materials for proof-of-concept studies and in process development on the route to market. In segregated cGMP facilities, HFR produces from grammes to multi-kilos of Active Pharmaceutical Ingredients and their intermediates for pre-clinical studies and early clinical trials.
Dr Stella JamesHead of Business Development
Karma Oncology Ltd
Karma Oncology Ltd. is a specialized oncology clinical development company, working for the pharmaceutical and biotechnology industries globally. From the preparation of clinical development plans through design, set up, monitoring, management and reporting of clinical trials, Karma Oncology provides a bespoke service.
Dr Karen WilliamsPresident
Mrs Tracey HamillClinical Project Manager/Business Development Manager
Exhibiting at booth 82
PHASTAR work with pharmaceutical and biotechnology companies to provide statistical consulting and to collect, summarise, analyse and report the data used in clinical trials. Our top priority is the quality of our work, ensuring we give you the best statistical advice, and analyse your clinical data optimally, getting it right first time. There are lots of different ways to analyse a set of data. We can advise on how to get the most out of your data. Statistics is an art!
We can work with our own internal systems and processes or seamlessly incorporate with your teams. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.
Mr Kevin KaneCEO
Seda Pharmaceutical Development Services Ltd
Exhibiting at booth 83/84
The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.
By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.
Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.
Strategy > Design > Data > Interpretation > Execution
- Physicochemical characterisation and preformulation studies
- Solid form selection including polymorphs, salts and co-crystals
- Preclinical safety study formulation development for challenging molecules
- First-time-in-clinic and later phase / commercial formulation development
- Enabling formulations and specialist drug delivery technology selection
- Preclinical DMPK
- Absorption and PK-PD Modeling
- GMP Audits
- Quality Systems (GMP supply aspects) for Clinical Study Sponsors
- Clinical pharmacokinetics and Biopharmaceutics
- Due diligence, competitor analysis and technology opportunity assessments
- Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards
Routes of administration and technology areas we cover:
- Immediate release
- Modified release
- Oral poorly solubles
- Poorly soluble IV
Dr Paul DickinsonDirector
Dr Marcel de MatasDirector
Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.
Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated. USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.
Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.
Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.
Areas of Expertise:
• Medicinal chemistry: Tool compounds; peptides; macrocycles; natural product chemistry
• Biology: Assay development
• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology
• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions
• 14C Custom Radiosynthesis
• GMP 14C Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds